Write a proper prescription sheet for an adult patient with type 2 diabetes mellitus who is currently taking metformin 500 mg twice daily and sitagliptin 50 mg daily and has fasting glucose consistently above 130 mg/dL.

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: February 24, 2026View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Prescription Sheet for Adult Patient with Type 2 Diabetes Mellitus


Patient Name: ___________________________
Date: ___________________________
Medical Record Number: ___________________________
Date of Birth: ___________________________
Weight: ___________ kg


Current Medications

  1. Metformin 500 mg – Take 1 tablet by mouth twice daily with meals
  2. Sitagliptin 50 mg – Take 1 tablet by mouth once daily

New Prescriptions

1. Insulin Glargine (Lantus) 100 units/mL

  • Dose: Start with 10 units subcutaneously once daily at bedtime (or 0.1–0.2 units/kg if weight-based dosing preferred) 1
  • Administration: Inject subcutaneously in the abdomen, thigh, or upper arm at the same time each evening 1
  • Titration Schedule:
    • Increase dose by 2 units every 3 days if fasting glucose is 140–179 mg/dL 1
    • Increase dose by 4 units every 3 days if fasting glucose is ≥180 mg/dL 1
    • Target fasting glucose: 80–130 mg/dL 1
    • If any glucose reading falls <70 mg/dL, reduce the current dose by 10–20% immediately and treat with 15 g fast-acting carbohydrate 1
  • Critical threshold: When basal insulin approaches 0.5 units/kg/day without achieving glycemic targets, consider adding prandial insulin rather than continuing to escalate basal insulin alone to avoid "over-basalization" 1
  • Dispense: 1 vial (10 mL) or 5 FlexTouch pens (3 mL each)
  • Refills: 3

2. Metformin Extended-Release (ER) 1000 mg

  • Dose: Take 1 tablet by mouth once daily with the evening meal 2
  • Rationale: Continue metformin at maximum tolerated dose (up to 2000–2550 mg daily) when adding insulin; metformin reduces total insulin requirements by 20–30% and provides superior glycemic control compared to insulin alone 1
  • Monitoring: Check eGFR at least annually if ≥60 mL/min/1.73 m²; increase to every 3–6 months if eGFR <60 mL/min/1.73 m² 2, 3
  • Dose adjustment for renal function:
    • eGFR ≥60: Continue standard dosing 3
    • eGFR 45–59: Continue current dose with increased monitoring 3
    • eGFR 30–44: Reduce dose to 1000 mg daily (half the standard dose) 3
    • eGFR <30: Discontinue metformin immediately 3
  • Dispense: 90 tablets
  • Refills: 3

3. Sitagliptin 100 mg

  • Dose: Take 1 tablet by mouth once daily 4, 5
  • Rationale: Adding sitagliptin to metformin provides an additional 0.5–0.8% HbA1c reduction, improves beta-cell function, and is generally well-tolerated with minimal hypoglycemia risk 4, 5, 6
  • Renal adjustment: If eGFR falls to 30–44 mL/min/1.73 m², reduce to 50 mg daily; if eGFR <30 mL/min/1.73 m², reduce to 25 mg daily 3
  • Dispense: 90 tablets
  • Refills: 3

4. Blood Glucose Test Strips and Lancets

  • Frequency: Check fasting glucose daily during insulin titration 1
  • Additional monitoring: Check pre-meal glucose if prandial insulin is added later 1
  • Dispense: 100 test strips and 100 lancets per month
  • Refills: 3

5. Glucose Meter (if not already provided)

  • Dispense: 1 glucose meter with instruction manual
  • Refills: 0

Patient Education and Safety Instructions

Insulin Administration

  • Inject insulin glargine at the same time each evening (preferably at bedtime) 1
  • Rotate injection sites within the same anatomical region to prevent lipohypertrophy 1
  • Never share insulin pens, needles, or syringes between patients 7

Hypoglycemia Management

  • Treat any glucose <70 mg/dL immediately with 15 g of fast-acting carbohydrate (4 glucose tablets or 4 oz juice), recheck in 15 minutes, and repeat if needed 1
  • Symptoms include shakiness, sweating, confusion, rapid heartbeat 1
  • Always carry a source of fast-acting carbohydrate 1

Monitoring Requirements

  • Check fasting glucose every morning during titration 1
  • Record all glucose values to guide dose adjustments every 3 days 1
  • Contact provider if fasting glucose remains >180 mg/dL after 2–3 weeks of titration 1
  • Contact provider immediately if glucose falls <70 mg/dL 1

Sick Day Management

  • Continue insulin even if not eating to prevent ketoacidosis 1
  • Check glucose every 4 hours during illness 1
  • Maintain adequate hydration 1
  • Temporarily discontinue metformin during acute illness causing volume depletion (severe infection, diarrhea, vomiting, dehydration) 3

Metformin Safety

  • Take metformin with meals to minimize gastrointestinal side effects 2
  • Hold metformin before iodinated contrast procedures if you have liver disease, alcoholism, or heart failure; re-check eGFR 48 hours after procedure before restarting 3
  • Monitor for vitamin B12 deficiency if on metformin for >4 years 2, 3

Follow-Up Plan

Week 1–3 (Titration Phase)

  • Patient self-adjusts insulin dose every 3 days based on fasting glucose readings using the titration schedule above 1
  • Daily fasting glucose monitoring 1

Week 4

  • Office visit to review glucose log, assess for hypoglycemia, and evaluate overall glycemic control 1
  • Check HbA1c if not done in past 3 months 8

Month 3

  • Office visit to reassess HbA1c and determine if further intensification is needed 1
  • If HbA1c remains >7% despite achieving fasting glucose 80–130 mg/dL, consider adding prandial insulin 1
  • If basal insulin dose approaches 0.5 units/kg/day without achieving targets, add prandial insulin (start with 4 units before the largest meal) 1

Ongoing

  • Monitor eGFR at least annually if ≥60 mL/min/1.73 m²; every 3–6 months if <60 mL/min/1.73 m² 2, 3
  • Check HbA1c every 3 months during intensive titration 1
  • Assess for cardiovascular disease, heart failure, or chronic kidney disease; if present, consider adding SGLT2 inhibitor or GLP-1 receptor agonist with proven cardiovascular benefit 8

Common Pitfalls to Avoid

  • Do not delay insulin initiation in patients not achieving glycemic goals with oral medications; prolonged hyperglycemia increases complication risk 1
  • Do not discontinue metformin when starting insulin unless contraindicated; this leads to higher insulin requirements and more weight gain 1
  • Do not continue escalating basal insulin beyond 0.5–1.0 units/kg/day without addressing postprandial hyperglycemia; this causes over-basalization with increased hypoglycemia risk 1
  • Do not use sliding-scale insulin as monotherapy; it is condemned by major diabetes guidelines and causes dangerous glucose fluctuations 1

Prescriber Signature: ___________________________
Prescriber Name (Print): ___________________________
License Number: ___________________________
DEA Number (if applicable): ___________________________
Date: ___________________________


Contact Information for Questions:
Phone: ___________________________
After-Hours Emergency: ___________________________

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.